ClinicalTrials.gg

Program

blinatumomab

Also written as “Blinatumomab”, “MEDI-538” and “Blinatumomab (MT103)”.

Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma · Lymphoma, Large B-Cell, Diffuse · Neoplasm, Residual · Lymphoma, Non-Hodgkin · Lymphoma, B-Cell, led by 4 companies.

Furthest: phase 4, since Jul 27, 202029 company-led studies, 7 open or runningNext primary completion: Nov 24, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen256 open or runningphase 4since Jul 27, 2020Jan 10, 2006Nov 24, 2027phase 2 · NCT04521231
AstraZeneca20 open or runningphase 2since May 8, 2008Sep 28, 2007none ahead
Imugene10 open or runningphase 1since Sep 14, 2023Sep 14, 2023none ahead
Novartis11 open or runningphase 2since Jan 13, 2026Jan 13, 2026Sep 19, 2033phase 2 · NCT07387926

Also a collaborator on its studies: BeOne Medicines, Merck and amgen-astellas-biopharma-k-k.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 16 studies since Jan 10, 2006.

  1. Sep 12, 2017Phase 2 study in High-risk Diffuse Large B-cell LymphomaAmgen · NCT03298412 · 10 enrolled · United States, Australia, Belgium and more
  2. Oct 23, 2017Phase 1 study in RecurrenceAmgen · NCT03340766 · 31 enrolled · United States, Australia, France and more
  3. Mar 12, 2018Phase 3 study in Precursor Cell Lymphoblastic Leukemia-LymphomaAmgen · NCT03476239 · 121 enrolled · China
  4. Jul 27, 2020Phase 4 study in LeukemiaAmgen · NCT04506086 · 10 enrolled · United States
  5. Aug 18, 2020Phase 2 study in RecurrenceAmgen · NCT04521231 · 181 enrolled · United States, Argentina, Australia and more
  6. Jul 30, 2021Phase 3 study in Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Amgen · NCT04994717 · 303 enrolled · United States, Australia, Austria and more
  7. Sep 14, 2023Imugene's first study: phase 1 study in Bites and StingsNew to ImugeneImugene · NCT06063317 · 25 enrolled · United States
  8. Sep 18, 2023Phase 2 study in RecurrenceAmgen · NCT06054113 · 18 enrolled · China
  9. Aug 22, 2024Phase 2 study in Lupus Erythematosus, SystemicAmgen · NCT06570798 · 220 planned · United States, Australia, Belgium and more
  10. Oct 17, 2024Phase 1 study in LeukemiaAmgen · NCT06649006 · 6 enrolled · Japan
  11. Aug 14, 2025Phase 2 study in RecurrenceAmgen · NCT07134088 · 104 enrolled · United States, Japan
  12. Oct 29, 2025Phase 3 study in Precursor Cell Lymphoblastic Leukemia-LymphomaAmgen · NCT07223190 · 560 planned
  13. Jan 13, 2026Novartis's first study: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNew to NovartisNovartis · NCT07387926 · 50 planned · Australia, France, Israel and more
  14. Oct 5, 2026Primary completion moved from 2028-12-05 to 2031-03-06Date moved laterphase 2 · +27 months · NCT07134088

Ahead

  1. Nov 24, 2027Primary completion: phase 2 study in RecurrenceAmgen · NCT04521231
  2. Aug 6, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicAmgen · NCT06570798
  3. Sep 7, 2029Primary completion: phase 3 study in Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Amgen · NCT04994717
  4. Mar 6, 2031Primary completion: phase 2 study in RecurrenceAmgen · NCT07134088

TargetBeta

CD19 →CD3E →read by rule
“T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
YK012ruleexcyte-biopharma-ltdphase 25
GSK5926371GlaxoSmithKlinephase 22
Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rulecullinan-therapeutics-incphase 14
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rulecytocares-incphase 14
Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565Novartisphase 13
ATG-201ruleantengene-biologics-limitedphase 11
KT501rulekali-therapeutics-incphase 11
KT502rulekali-therapeutics-incphase 11

Studies

All 29 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07387926Precursor Cell Lymphoblastic Leukemia-Lymphoma · Australia, France, Israel and more2RecruitingNovartisSep 19, 203350
NCT07223190Precursor Cell Lymphoblastic Leukemia-Lymphoma3Not yet recruitingAmgenDec 30, 2031560
NCT07134088Recurrence · United States, Japan2Active, not recruitingAmgenMar 6, 2031104
NCT06649006Leukemia · Japan1CompletedAmgenJul 30, 20256
NCT06570798Lupus Erythematosus, Systemic · United States, Australia, Belgium and more2RecruitingAmgenAug 6, 2028220
NCT06054113Recurrence · China2Active, not recruitingAmgenJan 6, 202618
NCT06063317Bites and Stings · United States1TerminatedImugeneFeb 2, 202625
NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) · United States, Australia, Austria and more3Active, not recruitingAmgenSep 7, 2029303
NCT04521231Recurrence · United States, Argentina, Australia and more2Active, not recruitingAmgenNov 24, 2027181
NCT04506086Leukemia · United States4TerminatedAmgenJul 4, 202410
NCT03476239Precursor Cell Lymphoblastic Leukemia-Lymphoma · China3CompletedAmgenAug 21, 2019121
NCT03340766Recurrence · United States, Australia, France and more1CompletedAmgenNov 6, 202031
NCT03298412High-risk Diffuse Large B-cell Lymphoma · United States, Australia, Belgium and more2TerminatedAmgenSep 30, 201910
NCT03023878High-risk Diffuse Large B-Cell Lymphoma · United States, Canada, France and more2CompletedAmgenApr 4, 201947
NCT02961881Lymphoma, Non-Hodgkin · United States, Australia, France and more1CompletedAmgenSep 2, 202135
NCT02910063Lymphoma, B-Cell · United States, Australia, Belgium and more3CompletedAmgenMar 12, 202041
NCT02393859Precursor Cell Lymphoblastic Leukemia-Lymphoma · Argentina, Australia, Austria and more3CompletedAmgenJul 17, 2019111
NCT02412306Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia · Japan2CompletedAmgenFeb 6, 201966
NCT02013167Recurrence · United States, Australia, Austria and more3TerminatedAmgenDec 29, 2015405
NCT02000427Recurrence · United States, France, Germany and more2CompletedAmgenMay 20, 201545
NCT01741792Lymphoma, Large B-Cell, Diffuse · Germany2CompletedAmgenJul 201425
NCT01471782Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Austria, Canada and more2CompletedAmgenAug 201493
NCT01466179Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, France, Germany and more2CompletedAmgenOct 2013225
NCT01209286Precursor Cell Lymphoblastic Leukemia-Lymphoma · Germany2CompletedAmgenMar 201236
NCT01207388Burkitt Lymphoma · Austria, Belgium, France and more2CompletedAmgenFeb 2014116
NCT00676871Leukemia, Lymphocytic, Chronic, B-Cell2WithdrawnAstraZenecaMar 201030
NCT00560794Precursor Cell Lymphoblastic Leukemia-Lymphoma · Germany2CompletedAmgenSep 200921
NCT00538096Lymphoma, B-Cell1WithdrawnAstraZenecaMar 201018
NCT00274742Lymphoma, Non-Hodgkin · Germany1CompletedAmgenAug 201176

How it is read

Names in the registry

  • “Blinatumomab”, 25 entries
  • “MEDI-538”, 10 entries
  • “Blinatumomab (MT103)”, 2 entries
  • “blinatumomab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.